[go: up one dir, main page]

ES2172669T3 - Generacion de respuestas inmunitarias a antigeno especifico de la prostata (psa). - Google Patents

Generacion de respuestas inmunitarias a antigeno especifico de la prostata (psa).

Info

Publication number
ES2172669T3
ES2172669T3 ES96923417T ES96923417T ES2172669T3 ES 2172669 T3 ES2172669 T3 ES 2172669T3 ES 96923417 T ES96923417 T ES 96923417T ES 96923417 T ES96923417 T ES 96923417T ES 2172669 T3 ES2172669 T3 ES 2172669T3
Authority
ES
Spain
Prior art keywords
psa
guest
prostate
immune response
additional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96923417T
Other languages
English (en)
Inventor
Jeffrey Schlom
Dennis L Panicali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therion Biologics Corp
US Department of Health and Human Services
Original Assignee
Therion Biologics Corp
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23988841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2172669(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Therion Biologics Corp, US Department of Health and Human Services filed Critical Therion Biologics Corp
Application granted granted Critical
Publication of ES2172669T3 publication Critical patent/ES2172669T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE DESCUBRE QUE UTILIZANDO UN VECTOR VIRAL RECOMBINANTE, PREFERENTEMENTE UN VECTOR DE POXVIRUS QUE POSEE AL MENOS UN SITIO DE INSERCION QUE CONTIENE UN SEGMENTO DE DNA QUE CODIFICA UN ANTIGENO ESPECIFICO DE PROSTATA (PSA), UNIDO DE FORMA OPERATIVA A UN PROMOTOR CAPAZ DE LA EXPRESION EN EL HUESPED, ES POSIBLE GENERAR UNA RESPUESTA ESPECIFICA HUMORAL Y CELULAR A PSA. EL METODO COMPRENDE PREFERENTEMENTE LA INTRODUCCION DE UNA CANTIDAD SUFICIENTE DEL VECTOR DE POXVIRUS RECOMBINANTE EN UN HUESPED PARA ESTIMULAR LA RESPUESTA INMUNITARIA, Y PONER EN CONTACTO EL HUESPED CON PSA ADICIONAL A INTERVALOS PERIODICOS CON POSTERIORIDAD. EL PSA ADICIONAL PUEDE AÑADIRSE UTILIZANDO UN SEGUNDO VECTOR POXVIRUS DE UN GENERO DE POXVIRUS DIFERENTE. EN OTRA REALIZACION, PUEDE AÑADIRSE PSA ADICIONAL PONIENDO EN CONTACTO EL HUESPED CON PSA MEDIANTE DIVERSOS OTROS METODOS, INCLUYENDO EN UNA REALIZACION PREFERIDA AÑADIR PSA. EL PSA PUEDE FORMULARSE EN UNA FORMULACION CON ADYUVANTE O LIPOSOMAS.
ES96923417T 1995-07-10 1996-06-26 Generacion de respuestas inmunitarias a antigeno especifico de la prostata (psa). Expired - Lifetime ES2172669T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/500,306 US6165460A (en) 1995-07-10 1995-07-10 Generation of immune responses to prostate-specific antigen (PSA)

Publications (1)

Publication Number Publication Date
ES2172669T3 true ES2172669T3 (es) 2002-10-01

Family

ID=23988841

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01113517T Expired - Lifetime ES2320089T3 (es) 1995-07-10 1996-06-26 Generacion de respuesta inmunes para antigenos especificos de prostata (spa).
ES96923417T Expired - Lifetime ES2172669T3 (es) 1995-07-10 1996-06-26 Generacion de respuestas inmunitarias a antigeno especifico de la prostata (psa).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01113517T Expired - Lifetime ES2320089T3 (es) 1995-07-10 1996-06-26 Generacion de respuesta inmunes para antigenos especificos de prostata (spa).

Country Status (11)

Country Link
US (2) US6165460A (es)
EP (2) EP1162272B8 (es)
JP (3) JP4633867B2 (es)
AT (2) ATE413459T1 (es)
CA (1) CA2226436C (es)
DE (2) DE69618601T2 (es)
DK (2) DK0840791T3 (es)
ES (2) ES2320089T3 (es)
HK (1) HK1042518B (es)
PT (2) PT1162272E (es)
WO (1) WO1997003203A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699475B1 (en) * 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
EP0954593A1 (en) * 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2003042370A2 (en) 2001-11-14 2003-05-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New gene expressed in prostate cancer and methods of use
BR0311720A (pt) * 2002-06-11 2005-03-01 Merck Patent Gmbh Método para mapear e eliminar epitopos de células t
DE10230893A1 (de) * 2002-06-26 2004-01-15 Dr. Fischer Ag Verfahren zur Eigenschaftsbestimmung und/oder Klassifikation von zirkulierenden Macrophagen und/oder peripheren blutmononuclearen Zellen sowie Analyseanordnung zur Durchführung des Verfahrens
WO2004056977A1 (en) * 2002-12-13 2004-07-08 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
WO2005005465A2 (en) * 2003-07-08 2005-01-20 Board Of Regents, University Of Texas System Methods and compositions to enhance immune responses via recall antigens
US20070196346A1 (en) * 2003-08-21 2007-08-23 Brown Michael P Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
US8293701B2 (en) * 2005-06-21 2012-10-23 Cellectis S.A. Methods and compositions relating to a vaccine against prostate cancer
EP2441493B1 (en) 2006-03-14 2014-05-07 Oregon Health and Science University Methods for producing an immune response to tuberculosis
EP2079760B1 (en) 2006-12-27 2016-04-27 Emory University Compositions and methods for the treatment of infections
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP2207564B1 (en) * 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
ES2547654T3 (es) * 2008-10-31 2015-10-07 Tremrx, Inc. Vacunación con vectores poxvirales mediante alteración mecánica epidérmica
CA2744449C (en) 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
EP3263124A1 (en) 2009-11-20 2018-01-03 Oregon Health&Science University Methods for producing an immune response to tuberculosis
EP3153861A3 (en) 2010-08-06 2017-06-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Biomarkers for predicting response to a cancer vaccine
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014097762A1 (ja) * 2012-12-20 2014-06-26 国立大学法人熊本大学 高病原性トリインフルエンザに対する抗体
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
JP5917626B2 (ja) * 2014-07-28 2016-05-18 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
CN115925878A (zh) 2015-06-05 2023-04-07 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
US10550164B2 (en) 2015-08-03 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
EP3941514A4 (en) * 2019-03-20 2023-08-30 Turnstone Biologics Inc. ONCOLYTIC VIROTHERAPY BY HETEROLOGY SEQUENTIAL BOOSTER
US12129302B2 (en) 2021-08-25 2024-10-29 Ibio, Inc. Anti-CD-25 antibody

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
CA2102623C (en) * 1991-05-06 2003-04-22 Jeffrey Schlom Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
WO1994009820A1 (en) * 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
DE69434475T2 (de) * 1993-08-11 2006-05-18 Jenner Technologies, Tiburon Impfstoff gegen prostatakrebs
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
EP0652014A1 (en) * 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
ZA941645B (en) * 1994-03-09 1995-01-13 South To South Co Operation In Antibodies specifically reactive against human prostate specific antigen.
EP0725139A3 (en) * 1995-02-03 1997-11-26 Bayer Corporation Recombinant prostate-specific antigen and its use as an immunoassay calibrator
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)

Also Published As

Publication number Publication date
HK1042518A1 (en) 2002-08-16
CA2226436C (en) 2006-11-07
ATE413459T1 (de) 2008-11-15
DK1162272T3 (da) 2009-03-09
EP0840791A2 (en) 1998-05-13
EP1162272B8 (en) 2010-03-10
EP1162272A3 (en) 2004-07-14
DE69637738D1 (de) 2008-12-18
EP1162272B1 (en) 2008-11-05
ATE212058T1 (de) 2002-02-15
PT840791E (pt) 2002-06-28
JP2008285492A (ja) 2008-11-27
JP4633867B2 (ja) 2011-02-16
US7598225B1 (en) 2009-10-06
HK1042518B (zh) 2009-04-17
DE69618601D1 (de) 2002-02-21
ES2320089T3 (es) 2009-05-19
EP0840791B1 (en) 2002-01-16
DE69618601T2 (de) 2002-08-08
US6165460A (en) 2000-12-26
EP1162272A2 (en) 2001-12-12
JP2006197938A (ja) 2006-08-03
PT1162272E (pt) 2009-02-16
CA2226436A1 (en) 1997-01-30
DK0840791T3 (da) 2002-03-18
JPH11509199A (ja) 1999-08-17
WO1997003203A2 (en) 1997-01-30
WO1997003203A3 (en) 1997-04-17

Similar Documents

Publication Publication Date Title
ES2172669T3 (es) Generacion de respuestas inmunitarias a antigeno especifico de la prostata (psa).
ATE77960T1 (de) Verwendung von interleukin-1 zur induzierung der bildung von multipotenten haemopoietischen zellpopulationen.
Clark et al. Lung connective tissue
ES2115679T3 (es) Preparacion de reactivos de tiempo de protrombina a partir de factor de tejido humano recombinante y de fosfolipidos sinteticos y naturales purificados.
MY100641A (en) Neutral metalloendopeptidase inhibitors in the treatment of hypertension.
DE3751997D1 (de) Aktives protein in humoraler hyperkalzemia, durch bösartigkeit verursacht
ATE90384T1 (de) Rekombinante virusproteine begleitet von lymphadenopathischem syndrom und/oder ''acquired immune deficiency syndrome'' (aids).
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
DK0600992T3 (da) Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
TR199801649T2 (xx) Ba����kl�k mod�lasyonu i�in farmaz�tik bile�imler.
ATE432085T1 (de) Stimulationsfaktor für dendriten
BR9500732A (pt) Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação
KR890000517A (ko) 하이브리드 단백질 c 및 이의 제조방법
ES2010727A6 (es) Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv.
NO983372D0 (no) Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter
DK21985A (da) Monoklonale antistoffer mod ikke-smaacellet lungecancer
ATE69108T1 (de) Elektrophoretisches gel hoher aufloesung sowie methode zur abscheidung von serumproteinen.
ES2139957T3 (es) Metodo para la determinacion del estado pretrombotico.
ATE189961T1 (de) Impfstoff gegen mycobakterielle infektionen
IT8419601A0 (it) Dispositivo per indicare e, oppure memorizzare errori di disposizioni di generatori su motori endotermici.
ATE46703T1 (de) Regionspezifische determinanten fuer vitamin-k abhaengiges knochenprotein.
MC1884A1 (fr) Variants de l'hirudine,leur utilisation et leur preparation
DE3855080D1 (de) Synoviale phospholipasen
NO872952D0 (no) Katode for bruk i hydrogenutviklende elektrokjemiske prosesser, samt fremgangsmaate til fremstilling av katoden.
DE3676896D1 (de) Verfahren zur herstellung von hexamethylcyclotrisilazan.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 840791

Country of ref document: ES